Sanibel Captiva Trust Company Inc. Trims Stake in Danaher Co. (NYSE:DHR)

by · The Markets Daily

Sanibel Captiva Trust Company Inc. trimmed its holdings in shares of Danaher Co. (NYSE:DHR – Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,074 shares of the conglomerate’s stock after selling 591 shares during the quarter. Sanibel Captiva Trust Company Inc.’s holdings in Danaher were worth $4,747,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Tsfg LLC raised its position in shares of Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock worth $25,000 after acquiring an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new position in shares of Danaher in the 2nd quarter worth $25,000. nVerses Capital LLC purchased a new position in shares of Danaher in the 2nd quarter worth $25,000. Redmont Wealth Advisors LLC purchased a new position in shares of Danaher in the 1st quarter worth $30,000. Finally, Richardson Financial Services Inc. purchased a new position in shares of Danaher in the 4th quarter worth $42,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 over the last three months. 11.10% of the stock is currently owned by insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $266.45 on Friday. The company has a 50-day simple moving average of $270.73 and a 200-day simple moving average of $258.92. Danaher Co. has a one year low of $182.09 and a one year high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The stock has a market capitalization of $197.36 billion, a price-to-earnings ratio of 45.16, a PEG ratio of 4.55 and a beta of 0.83.

Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the business posted $2.05 earnings per share. The business’s revenue was down 2.9% compared to the same quarter last year. On average, analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.41%. Danaher’s dividend payout ratio is currently 18.31%.

Analyst Ratings Changes

A number of equities analysts recently commented on DHR shares. The Goldman Sachs Group raised their target price on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Leerink Partners lifted their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Barclays lifted their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 24th. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. Finally, Stephens assumed coverage on Danaher in a research report on Tuesday, October 1st. They set an “overweight” rating and a $315.00 target price for the company. Seven investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $282.12.

View Our Latest Report on DHR

About Danaher

(Free Report)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).